Abramowitz Benjamin, Chadha Nisha, Kouchouk Amr, Alhabshan Rashed, Belyea David A, Lamba Tania
Glaucoma Department, Eye Consultants of Northern Virginia, Springfield, VA, USA.
Icahn School of Medicine at Mount Sinai/New York Eye and Ear, Eye and Vision Research Institute, New York, NY, USA.
Clin Ophthalmol. 2018 Aug 30;12:1599-1604. doi: 10.2147/OPTH.S167102. eCollection 2018.
The aim of this study was to prospectively compare the efficacy, safety, and tolerability of selective laser trabeculoplasty (SLT) vs micropulse laser trabeculoplasty (MLT) in reducing intraocular pressure (IOP) in open-angle glaucoma patients.
In all, 38 patients were randomized to 360° MLT and 31 patients were randomized to 360° SLT. IOP was measured at intervals of 1 hour and 1, 1-6, 6-12, 6-24, 24-36, and 36-52 weeks. Patients completed a survey 1 week after the procedure. Patients with end-stage, neovascular, uveitic, or angle-closure glaucoma were excluded. Treatment response was defined as an IOP reduction of ≥20.0% or ≥3 mmHg from baseline.
IOP was lowered to ≥3 mmHg from baseline among 37.0% of the micropulse patients and 36.0% of patients in the selective laser group at 24-52 weeks. Similarly, 29.6% of the micropulse patients and 36.0% of the selective laser patients experienced a 20.0% IOP decrease from baseline during the 24-52-week interval (=0.77). Both groups revealed similar reductions in IOP as absolute values and percentage decreases from baseline at all intervals up to 52 weeks post treatment. There were more treatment failures in the micropulse group up to 52 weeks post laser treatment; however, this was not statistically significant. The micropulse group reported less pain both during and after the procedure (=0.005).
Micropulse trabeculoplasty has demonstrated similar efficacy to SLT over a 52-week follow-up period with less discomfort experienced both during and after the procedure.
本研究旨在前瞻性比较选择性激光小梁成形术(SLT)与微脉冲激光小梁成形术(MLT)在降低开角型青光眼患者眼压方面的疗效、安全性和耐受性。
总共38例患者被随机分配接受360°MLT,31例患者被随机分配接受360°SLT。在术后1小时以及术后1周、1 - 6周、6 - 12周、6 - 24周、24 - 36周和36 - 52周测量眼压。患者在术后1周完成一项调查。终末期、新生血管性、葡萄膜炎性或闭角型青光眼患者被排除。治疗反应定义为眼压较基线降低≥20.0%或≥3 mmHg。
在24 - 52周时,微脉冲组37.0%的患者眼压较基线降低≥3 mmHg,选择性激光组为36.0%。同样,在24 - 52周期间,微脉冲组29.6%的患者眼压较基线降低20.0%,选择性激光组为36.0%(P = 0.77)。两组在治疗后至52周的所有时间间隔内,眼压的绝对值降低以及较基线的百分比降低情况相似。在激光治疗后至52周,微脉冲组的治疗失败病例更多;然而,这并无统计学意义。微脉冲组在术中及术后报告的疼痛较少(P = 0.005)。
在52周的随访期内,微脉冲小梁成形术显示出与SLT相似的疗效,且术中及术后不适较少。